XML 34 R23.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | ---
Jun. 30, 2018 | Jun. 30, 2018 | Jun. 30, 2017 | Jan. 01, 2018 | Dec. 31, 2017
Organization And Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Liquid investments purchased with original maturities |  | three months or less |  |  |
Accumulated deficit | $ (531,189) | $ (531,189) |  |  | $ (495,479)
Topic 606 [Member] |  |  |  |  |
Organization And Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Accumulated deficit |  |  |  | $ (494,362) |
Topic 606 [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] |  |  |  |  |
Organization And Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Accumulated deficit | (5,163) | (5,163) |  | $ 1,117 |
Deferred revenues | (5,200) | (5,200) |  |  |
ASU 2016-18 [Member] |  |  |  |  |
Organization And Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Restricted cash balance | 3,500 | 3,500 |  |  |
Pfizer [Member] |  |  |  |  |
Organization And Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Deferred revenues | 31,900 | 31,900 |  |  |
Increase in recognition of up-front payment amount | 1,600 | $ 2,600 |  |  |
Pfizer [Member] | Customer Concentration Risk [Member] | Total revenues [Member] |  |  |  |  |
Organization And Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Percentage of revenues |  | 47.00% |  |  |
Bioverativ Inc [Member] |  |  |  |  |
Organization And Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Deferred revenues | 6,200 | $ 6,200 |  |  |
Reduction in recognition of up-front payment amount | $ 700 | $ 1,500 |  |  |
Bioverativ Inc [Member] | Customer Concentration Risk [Member] | Total revenues [Member] |  |  |  |  |
Organization And Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Percentage of revenues |  | 26.00% | 48.00% |  |
Shire AG [Member] |  |  |  |  |
Organization And Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Deferred revenues |  |  |  |  | $ 2,300
Shire AG [Member] | Customer Concentration Risk [Member] | Total revenues [Member] |  |  |  |  |
Organization And Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Percentage of revenues |  |  | 11.00% |  |

X
- Definition Cash equivalent maturity period highly liquid investment. + References No definition available. + Details
Name: | sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment
Namespace Prefix: | sgmo_
Data Type: | invest:dateStringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Organization and summary of significant accounting policies. + References No definition available. + Details
Name: | sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems
Namespace Prefix: | sgmo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue increase in recognition of up front payment amount. + References No definition available. + Details
Name: | sgmo_RevenueIncreaseInRecognitionOfUpFrontPaymentAmount
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue reduction in recognition of up front payment amount. + References No definition available. + Details
Name: | sgmo_RevenueReductionInRecognitionOfUpFrontPaymentAmount
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 + Details
Name: | us-gaap_RestrictedCash
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 + Details
Name: | us-gaap_RetainedEarningsAccumulatedDeficit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201618Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_BioverativIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_ShireAgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |